Navigation Links
New MedPredict Report Highlights Recent Advances in Management of Malignant Hematology
Date:1/15/2010

SCOTTSDALE, Ariz., Jan. 15 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing therapies to treat hematologic malignancies.  These reports are based on primary interviews conducted with hematologists from North America immediately following the American Society of Hematology (ASH) annual meeting.

This report, entitled "Thought Leader Insight & Analysis – Malignant Hematology," includes analysis of new research in Multiple Myeloma, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Lymphoma, and Chronic Myelogenous Leukemia.  

"This report reflects on and analyzes the most important data presented at ASH, and clarifies the ways these data will change clinical practice," according to Jeff Berk, MedPredict president. "A key focus of the report is Multiple Myeloma (MM), which is being transformed into a chronic, but still life threatening disease.  The most exciting advances presented at ASH included both identifying the most effective combinations for induction therapy, and in establishing a role and practice standard for maintenance therapy in MM."

According to one MM Thought Leader interviewed for this report:  "I think the message was very positive in regards that maintenance matters, choice of induction strategy matters with less toxicity being important, and staying on treatment of some form or another is very critical."

The expert panel also discusses novel compounds in development for various hematologic malignancies, and the hurdles they will need to overcome to become viable options in this market.  

Companies and partnerships mentioned in this report includes: Allos, Ambit, Amgen, Arno Therapeutics, Antisoma, Biogen Idec/Elan, Biotest/ImmunoGen, Bristol-Myers Squibb, Bristol-Myers Squibb/Facet, Celgene, Celgene/Gloucester, Cephalon, ChemGenex, Cyclacel, Eisai, Genmab, Genzyme, Genzyme/Anormed, Genzyme/Bayer HealthCare Pharmaceuticals, Geron/Merck, GlaxoSmithKline, GlaxoSmithKline/Genmab, ImmunoGen, Immunomedics/Nycomed, Incyte, Keryx, Merck, Milteni Biotec, Novartis, Novartis/Vernalis, OXiGENE, PDL Biopharma, Proteolix/Onyx, Rigel, Seattle Genetics, Syndax, and Takeda/Millennium.

This report can be purchased by contacting MedPredict (www.medpredict.com).  

About MedPredict

MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories.  Based on primary interviews with these thought leaders, MedPredict publishes periodic reports to keep clients up-to-date on emerging trends and competitive activity.  The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict

RELATED LINKS
http://www.medpredict.com

'/>"/>

SOURCE MedPredict
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Landscape for Lung Cancer Therapies is Focus of New Post-ASCO MedPredict Report
2. Accuray Incorporated to Report Financial Results for Second Quarter of Fiscal 2010
3. New Report by BioTrends Research Group To Highlight The Launch Of ACTEMRA (tocilizumab)
4. Does the MS Market Need Another Interferon? Neurologists Provide Insight in the Wave One Report of LaunchTrends: EXTAVIA
5. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
6. BioTrends Publishes New Report Exploring Treatment Patterns for Anemia Across a Variety of Physician Specialties
7. Reportlinker Adds Negative Pressure Wound Therapy (NPWT) Pipeline Technology and Market Forecasts to 2016
8. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
9. Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition]
10. Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015
11. Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... Manhattan New york (PRWEB) , ... April 28, ... ... is pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic ... fellowship training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt ...
(Date:4/28/2017)... Edinburg, Texas (PRWEB) , ... April 28, 2017 , ... ... a plaque in recently to the labor and delivery team at Women’s Hospital at ... generous mothers who give birth at the hospital and decide to donate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
Breaking Medicine News(10 mins):